Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters










Database
Language
Publication year range
1.
Mol Biol Cell ; 33(4): ar33, 2022 04 01.
Article in English | MEDLINE | ID: mdl-35196065

ABSTRACT

The ARF family of regulatory GTPases is ancient, with 16 members predicted to have been present in the last eukaryotic common ancestor. Our phylogenetic profiling of paralogues in diverse species identified four family members whose presence correlates with that of a cilium/flagellum: ARL3, ARL6, ARL13, and ARL16. No prior evidence links ARL16 to cilia or other cell functions, despite its presence throughout eukaryotes. Deletion of ARL16 in mouse embryonic fibroblasts (MEFs) results in decreased ciliogenesis yet increased ciliary length. We also found Arl16 knockout (KO) in MEFs to alter ciliary protein content, including loss of ARL13B, ARL3, INPP5E, and the IFT-A core component IFT140. Instead, both INPP5E and IFT140 accumulate at the Golgi in Arl16 KO lines, while other intraflagellar transport (IFT) proteins do not, suggesting a specific defect in traffic from Golgi to cilia. We propose that ARL16 regulates a Golgi-cilia traffic pathway and is required specifically in the export of IFT140 and INPP5E from the Golgi.


Subject(s)
Fibroblasts , Phosphoric Monoester Hydrolases , Animals , Carrier Proteins/genetics , Carrier Proteins/metabolism , Cilia/metabolism , Fibroblasts/metabolism , Mice , Phosphoric Monoester Hydrolases/metabolism , Phylogeny , Protein Transport , Proteins/metabolism
2.
J Enzyme Inhib Med Chem ; 32(1): 992-1001, 2017 Dec.
Article in English | MEDLINE | ID: mdl-28766956

ABSTRACT

While progress has been made in treating cancer, cytotoxic chemotherapeutic agents are still the most widely used drugs and are associated with severe side-effects. Drugs that target unique molecular signalling pathways are needed for treating cancer with low or no intrinsic toxicity to normal cells. Our goal is to target hypoxic tumours and specifically the hypoxia inducible factor (HIF) pathway for the development of new cancer therapies. To this end, we have previously developed benzopyran-based HIF-1 inhibitors such as arylsulfonamide KCN1. However, KCN1 and its earlier analogs have poor water solubility, which hamper their applications. Herein, we describe a series of KCN1 analogs that incorporate a morpholine moiety at various positions. We found that replacing the benzopyran group of KCN1 with a phenyl group with a morpholinomethyl moiety at the para positions had minimal effect on potency and improved the water solubility of two new compounds by more than 10-fold compared to KCN1, the lead compound.


Subject(s)
Benzopyrans/pharmacology , Drug Design , Hypoxia-Inducible Factor 1/antagonists & inhibitors , Benzopyrans/chemical synthesis , Benzopyrans/chemistry , Solubility , Water/chemistry
SELECTION OF CITATIONS
SEARCH DETAIL
...